Companies / Lantern Pharma Inc.

Lantern Pharma Inc.

Nasdaq: LTRNCIK 1763950DALLAS, TX

Financials

Revenue—
Net income$-17.12M
Total debt—
Cash$4.92M
Diluted EPS$-1.57
Shares outstanding11.3M

Ownership

11.3M shares outstanding · as of May 12, 2026
0.83%Insiders
Ownership
Insiders0.83%94,303
Institutions20.54%2,322,111
Public float78.62%8,888,283

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Keyser D JeffreyDirector
0.83%94,303
Chandru VijayDirector
——
Maccecchini Maria-LuisaDirector
——
Schalop Lee TroyDirector
——
Silberstein David S.Director
——

Institutional holders 35

View all →
HolderValue% of shares
BIOS Capital Management, LP$3.06M8.93%
Vanguard Group Inc$1.16M3.40%
CM Management, LLC$681.8K1.99%
Quadrature Capital Ltd$165.1K0.35%
Renaissance Technologies LLC$158.9K1.03%
Geode Capital Management, LLC$153.0K0.99%
Voss Value Master Fund, LP$151.5K0.44%
Dimensional Fund Advisors LP$118.5K0.35%
NewEdge Advisors, LLC$115.4K0.34%
Westside Investment Management, Inc.$108.8K0.32%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 12, 2026Keyser D Jeffrey
Director
BuyCommon stock, $0.001 par value$100.0K+49K
+106.09%
94,303
0.83% of shares
medium
May 12, 2026Keyser D Jeffrey
Director
BuyCommon stock purchase warrant (Right to Buy)—-49K
-50.00%
48,544
0.43% of shares
low
Jan 9, 2026Chandru Vijay
Director
GrantStock Option (Right to Buy)—+17K
17,307
0.15% of shares
low
Jan 9, 2026Chandru Vijay
Director
GrantStock Option (Right to Buy)—+25K
25,000
0.22% of shares
low
Jan 9, 2026Silberstein David S.
Director
GrantStock Option (Right to Buy)—+17K
17,307
0.15% of shares
low
Jan 9, 2026Silberstein David S.
Director
GrantStock Option (Right to Buy)—+25K
25,000
0.22% of shares
low
Jan 9, 2026Schalop Lee Troy
Director
GrantStock Option (Right to Buy)—+18K
18,460
0.16% of shares
low
Jan 9, 2026Schalop Lee Troy
Director
GrantStock Option (Right to Buy)—+25K
25,000
0.22% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Thomas A. Satterfield, Jr.Passive13G———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
LTRN——51654W101—